-

Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced two upcoming presentations at the 93rd European Atherosclerosis Society (EAS) Congress being held May 4-7, 2025 in Glasgow, UK.

Details of the oral presentations are as follows:

Title: A Novel ANGPTL4 Inhibitory Antibody Safely Lowers Plasma Triglycerides and Remnant Cholesterol in Humans
Abstract Number: 1320
Session Title: Late Breaker Session: Clinical
Session Date and Time: Wednesday, May 7, 2025, 11:00 a.m. – 12:30 p.m. BST


Title: Real-world Analysis of the Association of Remnant Cholesterol Levels with Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease
Abstract Number: 1314
Session Title: SaaG Session: Epidemiology: From Prevention to Prognosis
Session Date and Time: Tuesday, May 6, 2025, 2:35 p.m. – 3:35 p.m. BST

About Marea Therapeutics

Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.

Contacts

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

Industry:

Marea Therapeutics, Inc.

Release Versions
English

Contacts

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

More News From Marea Therapeutics, Inc.

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first participant has been enrolled in Marea’s Phase 1 study evaluating MAR002 for the treatment of acromegaly. Acromegaly is a chronic, rare, systemic disease most often caused by a growth hormone (GH)-secreting pituitary adenoma,...

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first patient has been enrolled in Marea’s Phase 2b TYDAL-TIMI 78 study evaluating MAR001 in adults with elevated levels of triglycerides (TG) and remnant cholesterol (RC) at increased risk of atherosclerotic cardiovascular disease...

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Developmen...
Back to Newsroom